Evolent's Deep Loss Masks Ambitious Growth Bet

WASHINGTON, DC – February 24, 2026 – Evolent Health, Inc. (NYSE: EVH) today presented a starkly divided financial narrative, reporting a staggering $579.4 million net loss for 2025 while simultaneously forecasting an aggressive 30% revenue surge for 2026. The results paint a picture of a company undergoing a significant, and costly, strategic transformation, betting that its specialized healthcare solutions can outpace near-term financial pressures.

The full-year results were dominated by a massive $429.1 million net loss in the fourth quarter alone, driven primarily by a non-cash goodwill impairment charge of $398 million. This accounting write-down pushed the company deep into the red on a GAAP basis, yet executives pointed towards a different set of numbers to tell their story: positive Adjusted EBITDA and a pipeline swelling with over $900 million in new revenue for the coming year.

"In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model," stated Seth Blackley, Co-Founder and Chief Executive Officer of Evolent. He projected that the company's forecasted revenue growth "demonstrates the power and durability of Evolent's specialty model."

A Tale of Two Ledgers

The vast chasm between Evolent's GAAP net loss and its non-GAAP adjusted earnings highlights the complex financial maneuvering required to operate in the value-based healthcare space. For the full year 2025, the reported net loss of $(579.4) million stood in sharp contrast to a positive Adjusted EBITDA of $151.1 million.

The primary culprit for this discrepancy was the $398 million goodwill impairment. Goodwill, an intangible asset recorded during acquisitions, represents the premium paid over the fair value of the assets purchased. An impairment charge signifies that the company has determined the future cash flows from a previously acquired business will not be as high as once projected, forcing a write-down of its value. While it is a non-cash charge that doesn't affect day-to-day operations or cash flow, it is a significant flag for investors about the long-term value of past investments.

Evolent, like many companies, uses non-GAAP measures such as Adjusted EBITDA to present what it considers a clearer view of its core operational profitability. This metric strips out the goodwill impairment along with other items like stock-based compensation, transaction costs, and amortization expenses. The company argues this allows for a better understanding of its underlying performance, which in 2025, remained profitable on this adjusted basis with an 8.1% margin, consistent with the prior year.

Fueling the 2026 Growth Engine

Despite the jarring GAAP loss, Evolent's leadership is squarely focused on the future, issuing robust guidance that projects total revenue to reach between $2.4 billion and $2.6 billion in 2026. This represents a roughly 30% increase over 2025's $1.88 billion, a growth rate fueled by significant new business in its core specialty care division.

The company expects to add approximately $900 million in new Performance Suite revenue in 2026. A cornerstone of this growth is a major new contract with Highmark, which is slated to launch on May 1 and is expected to contribute over $550 million in revenue in 2026 alone, ramping up to over $800 million in 2027. This follows other significant wins announced in late 2025, including contracts with a large Blue Cross plan and a provider-sponsored health plan in the Southwest.

A key part of this strategy is the migration of clients to an "enhanced Performance Suite contract model." This new structure is designed to create more predictable margins by incorporating risk corridors and other adjustments that protect both Evolent and its health plan partners from extreme fluctuations in medical costs. With about 90% of its Performance Suite revenue now under this model, Evolent is aiming for more stable, long-term margins in the 7-10% range for this business line. The company's strategic focus is increasingly on high-cost, complex conditions, with oncology poised to become its dominant service line, projected to represent approximately 65% of total revenue in 2026, up from just 36% in 2025.

Navigating Market Headwinds and Rising Costs

The path to growth is not without its challenges. While revenue is set to soar, Evolent's Adjusted EBITDA is forecasted to be in the range of $110 million to $140 million for 2026—a potential decrease from the $151 million reported in 2025. This counterintuitive guidance reveals the pressures facing the company.

CEO Seth Blackley acknowledged the initial margin impact, citing "new contract reserving effects" and "significant health plan customer membership decreases in their Exchange products." This membership contraction, linked to broader health insurance market trends, is expected to create a one-time headwind of approximately $40 million. Furthermore, the company anticipates that margins will be back-end loaded, with about 70% of the year's Adjusted EBITDA expected in the second half of 2026 as the initial reserving for new contracts eases and cost-saving measures take full effect.

To combat these pressures, Evolent is embarking on a significant cost reduction plan, targeting roughly $50 million in savings for 2026. This initiative is heavily reliant on technology and automation, building on the acquisition of Machinify Auth's AI assets in 2024. The company is deploying AI-driven tools, such as its Copilot for musculoskeletal workflows, to drive efficiency and streamline operations.

This dual strategy of aggressive growth paired with disciplined cost control underscores the high-stakes environment Evolent operates in. The company is positioning itself as an indispensable partner for health plans struggling to manage the escalating costs of specialty care, particularly in oncology, cardiology, and musculoskeletal conditions. The robust demand for these solutions provides a powerful tailwind, but Evolent must carefully navigate the financial complexities of its value-based contracts and broader market volatility to turn its impressive revenue growth into sustained profitability.

The coming year will be a critical test of whether Evolent's specialized model can successfully balance the quality and affordability of care for patients while delivering financial stability and value for its shareholders.